Research Information System
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2022 (SCI-Expanded)
Purpose of the study The aim of this study is to evaluate the effect of apigenin on inflammatory response in brain tissue in Parkinson's mouse model. Materials and methods Parkinson's disease model was induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sixty 8-10-weeks-old male C57BL/6 mice were randomly divided into four groups control, Parkinson, prophylaxis, and treatment. Control (0.9% NaCl 0.5 ml, 10 days, i.p.), Parkinson (25 mg/kg MPTP, 5 days, i.p.), prophylaxis (50 mg/kg apigenin, 5 days + 25 mg/kg MPTP, 5 days, i.p.), and treatment (25 mg/kg MPTP, 5 days + 50 mg/kg apigenin, 5 days). The expressions and protein levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-1 beta), IL-6, IL-10, and transforming growth factor-beta (TGF-beta) were determined using immunohistochemistry and enzyme-linked immunosorbent analysis. Results Apigenin administration attenuated MPTP-induced histopathological changes in brain tissue. Furthermore, apigenin reversed the changes in expressions and concentrations of TNF-alpha, IL-1 beta, IL-6, IL-10, and TGF-beta. Conclusion This study suggests that apigenin could be used as a neuroprotective option to attenuate neuroinflammation in Parkinson's disease.